Statements (50)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:Monoamine_oxidase_inhibitors
|
| gptkbp:activities |
inhibition of monoamine oxidase
|
| gptkbp:approves |
gptkb:1959
gptkb:FDA |
| gptkbp:brand |
Marplan
|
| gptkbp:class |
hydrazine derivative
|
| gptkbp:clinical_trial |
studied for PTSD
studied for anxiety disorders studied for panic disorder studied for social anxiety disorder |
| gptkbp:contraindication |
gptkb:pheochromocytoma
liver disease concurrent use of certain medications |
| gptkbp:dosage_form |
10 to 20 mg daily
|
| gptkbp:duration |
long-term use
|
| https://www.w3.org/2000/01/rdf-schema#label |
Isocarboxazid
|
| gptkbp:ingredients |
C12 H13 N3 O3
|
| gptkbp:interacts_with |
tricyclic antidepressants
sympathomimetics SSR Is meperidine |
| gptkbp:invention |
patented
|
| gptkbp:is_available_on |
gptkb:tablet
|
| gptkbp:is_monitored_by |
gptkb:weight
mood blood pressure |
| gptkbp:is_used_for |
treatment of depression
|
| gptkbp:lifespan |
2 to 4 hours
|
| gptkbp:manager |
oral
|
| gptkbp:marketed_as |
various pharmaceutical companies
|
| gptkbp:metabolism |
liver
|
| gptkbp:premiered_on |
1 to 2 weeks
|
| gptkbp:requires |
requires dietary restrictions
|
| gptkbp:side_effect |
dizziness
insomnia dry mouth weight gain orthostatic hypotension |
| gptkbp:social_structure |
carboxylic acid
aromatic ring hydrazine group |
| gptkbp:status |
ongoing studies
|
| gptkbp:storage |
room temperature
|
| gptkbp:symptoms |
anxiety
headache nausea irritability |
| gptkbp:type_of |
59-73-2
|